American Society of Clinical OncologyGenomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report from an International Consortium

Despite aggressive therapy, the 5-year survival rate for patients with metastatic or recurrent rhabdomyosarcoma – the most common soft tissue sarcoma of childhood – remains poor, and beyond PAX-FOX01 fusion status, no genomic markers are available for risk stratification. This international consortium study was designed to determine the incidence of driver mutations and their association […]

American Medical AssociationAssessment of 25-Year Survival of Women with ER+/ERBB2- Breast Cancer Treated w. and without Tamoxifen Therapy

This Original Investigation from JAMA Network Open assesses whether clinically used markers of breast cancer, such as tumor size, tumor grade, progesterone receptor status, and Ki-67 status, are associated with long-term (25-year) survival as they are with short-term survival. The study was a secondary analysis of data from a subset of 565 women who participated […]

American Medical AssociationAssociation of Breast Cancer Irradiation With Cardiac Toxic Effects

In this JAMA Oncology Narrative Review, the authors attempt to discover whether cardiovascular risks may be associated with the multimodal approach, including systemic therapies and breast radiotherapy (RT), in treating breast cancer patients. Although recent advancements in breast cancer treatment have led to a decrease in mortality rates, the prevalence of survivors with a potentially […]

HMP CommunicationsDurvalumab Reduces Mortality Risk vs Chemo in NSCLC With PD-L1 Expression

Although the MYSTIC phase 3 clinical trial examining durvalumab therapy for non–small-cell lung cancer (NSCLC) did not meet its primary end points – overall survival (OS) and progression-free survival (PFS) – it did show a numerically reduced risk for death with durvalumab (Imfinzi) versus chemotherapy in patients with PD-L1 expression on ≥25% of tumor cells.

M3These 5 States are Healthcare Rock Stars—Did Yours Make the List?

US News & World Report recently published its state healthcare rankings, based on three measures: access to healthcare, quality of care, and overall health of the population, measuring rates of obesity, smoking, suicide, mental health, and mortality for adults and infants. At the top, Hawaii was the clear winner. At the bottom, Mississippi. Where does […]

M3The Common Drug That Reduces Cancer Risk (and No, It’s Not Aspirin)

Although initial animal studies indicated this drug might increase the risk of cancer, current research is showing the opposite. In a large systematic review and meta-analysis, for example, researchers showed that patients who took these drugs before their cancer diagnosis had a 21% lower risk of all-cause mortality and a 31% lower risk of cancer-specific […]

Millennium Medical PublishingCurrent Antibody-Based Therapies for the Treatment of Multiple Myeloma

Published in Clinical Advances in Hematology & Oncology, this article presents an overview of the currently available monoclonal antibody treatments in multiple myeloma (MM), discussing  the clinical value, significant potential, and possible limitations of these immunotherapeutic approaches to driving deeper responses and achieving longer overall survival among patients with a challenging disease.

Everyday HealthGreen Tea, Coffee, and Mortality Risk in T2DM

In this article from MedPage Today, drinking green tea and coffee was associated with reduced all-cause mortality in Japanese patients with type 2 diabetes, especially those who drank both, researchers reported. In a cohort study that followed nearly 5,000 patients for approximately five years, the researchers found a dose-response relationship for both beverages.